Andere Sprachen Harmony Biosciences Holdings, Inc.

Aktien

A2QBSF

US4131971040

HRMY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
29,32 ^USD	+1,35 %		-0,27 %	-9,23 %

11.04.	Harmony Biosciences und Bioprojet schließen Lizenzvertrag für Schlafstörungstherapie	MT
03.04.	Harmony Biosciences beginnt Phase-3-Studie mit Pitolisant zur Behandlung von Symptomen des Prader-Willi-Syndroms	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024	16.04.
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST	12.04.
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	11.04.
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	03.04.
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME	03.04.
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	03.04.
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	26.03.
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	19.03.
Harmony Biosciences Certified as a Great Place to Work for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth	07.03.
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES	28.02.
HARMONY BIOSCIENCES EXPANDS COMMITMENT TO THE RARE NEUROLOGICAL DISEASE COMMUNITY WITH CALL FOR PROGRESS AT THE HEART AND PATIENTS AT THE HEART APPLICATIONS	27.02.
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	22.02.
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	22.02.
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91	22.02.
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	22.02.
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024	22.02.
North American Morning Briefing : Nvidia Ignites -2-	22.02.
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Harmony Biosciences Holdings, Inc.

Aktien

A2QBSF

US4131971040

HRMY

Andere Sprachen

Filter